Phase 2
UNITY Biotechnology reported that the 12-week results from its Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
A COVID-19 vaccine candidate developed by Chinese pharmaceutical company Sinopharm triggered antibody-based immune responses in early and mid-stage trials.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 14, 2020.
A recent report in the New England Journal of Medicine reveals that the racial and ethnic minority groups most negatively-impacted by COVID-19 are also the least represented in these clinical studies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 7, 2020.
Denmark-based Lundbeck discontinued a mid-stage proof of concept study of a schizophrenia drug following an interim analysis of data that indicated the study will not achieve statistical significance in its primary endpoint.
PRESS RELEASES